The biologic revolution finally arrived for atopic dermatitis (AD) in 2017, with the approval of dupilumab, heralding a new era with many other agents in active development.^1,2 Significant improvement in disease severity measures and a number of quality-of-life measures have raised the bar for AD treatment, mirroring the more stringent treatment goals that have been defined for patients with psoriasis.³

中文翻译：

---

断奶或撤回Dupilumab治疗时的注意事项-永无止境。

在dupilumab的批准下，针对特应性皮炎（AD）的生物革命终于在2017年到来，预示着许多其他药物正在积极开发的新时代。^{1 ，2}中的疾病严重程度的措施显着改善和多项质量的寿命的措施提高了对治疗AD的栏中，镜像已为牛皮癣患者中定义的更严格的治疗目标。³